Background Brain metastasis is a major complication of breast cancer. This study aimed to analyze the effect of age and biological subtype on the risk and timing of brain metastasis in breast cancer patients. Patients and Methods We identified subtypes of invasive ductal carcinoma of the breast by determining estrogen receptor, progesterone receptor and HER2 status. Time to brain metastasis according to age and cancer subtype was analyzed by Cox proportional hazard analysis. Results Of the 2248 eligible patients, 164 (7.3%) developed brain metastasis over a median follow-up of 54.2 months. Age 35 or younger, HER2-enriched subtype, and triple-negative breast cancer were significant risk factors of brain metastasis. Among patients aged 35 or younger, the risk of brain metastasis was independent of biological subtype (P = 0.507). Among patients aged 36–59 or >60 years, those with triple-negative or HER2-enriched subtypes had consistently increased risk of brain metastasis, as compared with those with luminal A tumors. Patients with luminal B tumors had higher risk of brain metastasis than luminal A only in patients >60 years. Conclusions Breast cancer subtypes are associated with differing risks of brain metastasis among different age groups. Patients age 35 or younger are particularly at risk of brain metastasis independent of biological subtype.
References
[1]
Mayer M (2007) A patient perspective on brain metastases in breast cancer. Clin Cancer Res 13: 1623–1624. doi: 10.1158/1078-0432.ccr-06-2842
[2]
Benjamin L, Cotte FE, Mercier F, Vainchtock A, Vidal-Trécan G, et al. (2012) Burden of breast cancer with brain metastasis: a French national hospital database analysis. J Med Econ 15: 493–499. doi: 10.3111/13696998.2012.662924
[3]
Barnholtz-Sloan JS, Sloan AE, Davis FG, Vigneau FD, Lai P, et al. (2004) Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J Clin Oncol 22: 2865–2872. doi: 10.1200/jco.2004.12.149
[4]
Lin NU, Bellon JR, Winer EP (2004) CNS metastases in breast cancer. J Clin Oncol 22: 3608–3617. doi: 10.1200/jco.2004.01.175
[5]
Heitz F, Harter P, Lueck HJ, Fissler-Eckhoff A, Lorenz-Salehi F, et al. (2009) Triple-negative and HER2-overexpressing breast cancers exhibit an elevated risk and an earlier occurrence of cerebral metastases. Eur J Cancer 45: 2792–2798. doi: 10.1016/j.ejca.2009.06.027
[6]
Heitz F, Rochon J, Harter P, Lueck HJ, Fisseler-Eckhoff A, et al. (2011) Cerebral metastases in metastatic breast cancer: disease-specific risk factors and survival. Ann Oncol 22: 1571–1581. doi: 10.1093/annonc/mdq625
[7]
Tsukada Y, Fouad A, Pickren JW, Lane WW (1983) Central nervous system metastasis from breast carcinoma. Autopsy study. Cancer 52: 2349–2354. doi: 10.1002/1097-0142(19831215)52:12<2349::aid-cncr2820521231>3.0.co;2-b
[8]
Evans AJ, James JJ, Cornford EJ, Chan SY, Burrell HC, et al. (2004) Brain metastases from breast cancer: identification of a high-risk group. Clin Oncol (R Coll Radiol) 16: 345–349. doi: 10.1016/j.clon.2004.03.012
[9]
Duchnowska R, Dziadziuszko R, Czartoryska-Arlukowicz B, Radecka B, Szostakiewicz B, et al. (2009) Risk factors for brain relapse in HER2-positive metastatic breast cancer patients. Breast Cancer Res Treat 117: 297–303. doi: 10.1007/s10549-008-0275-z
[10]
Gonzalez-Angulo AM, Cristofanilli M, Strom EA, Buzdar AU, Kau SW, et al. (2004) Central nervous system metastases in patients with high-risk breast carcinoma after multimodality treatment. Cancer 101: 1760–1766. doi: 10.1002/cncr.20530
[11]
Nguyen PL, Taghian AG, Katz MS, Niemierko A, Abi Raad RF, et al. (2008) Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. J Clin Oncol 26: 2373–2378. doi: 10.1200/jco.2007.14.4287
[12]
Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, et al. (2011) Strategies for subtypes–dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 22: 1736–1747. doi: 10.1093/annonc/mdr304
[13]
National Comprehensive Cancer Network (2013) NCCN Clinical Practice Guidelines in Brest cancer, 2013 Verson I. Avalible: http://www.nccn.org/professionals/physic？ian_gls/pdf/breast.pdf.Accessed Febuary 28, 2013.
[14]
Rakha EA, El-Sayed ME, Lee AH, Elston CW, Grainge MJ, et al. (2008) Prognostic Significance of Nottingham Histologic grade in invastive breast carcinoma. J Clin Oncol 26: 3153–3158. doi: 10.1200/jco.2007.15.5986
[15]
Beadle BM, Woodward WA, Buchholz TA (2011) The impact of age on outcome in early-stage breast cancer. Semin Radiat Oncol 21: 26–34. doi: 10.1016/j.semradonc.2010.09.001
[16]
Isaiah JF (2003) The Pathogenesis of Cancer Metastasis: the’seed and soil’ hypothesis revisited. Nature reviews Cancer 3: 453–458. doi: 10.1038/nrc1098
[17]
Arvold ND, Taghian AG, Niemierko A, Abi Raad RE, Sreedhara M, et al. (2011) Age, breast cancer subtype approximation, and local recurrence after breast-conserving therapy. J Clin Oncol 29: 3885–3891. doi: 10.1200/jco.2011.36.1105
[18]
Kennecke H, Yerushalmi R, Woods R, Cheang MC, Voduc D, et al. (2010) Metastatic behavior of breast cancer subtypes. J Clin Oncol 28: 3271–3277. doi: 10.1200/jco.2009.25.9820
[19]
El Saghir NS, Seoud M, Khalil MK, Charafeddine M, Salem ZK, et al. (2006) Effects of young age at presentation on survival in breast cancer. BMC Cancer 6: 194. doi: 10.1186/1471-2407-6-194
[20]
Aebi S, Gelber S, Castiglione-Gertsch M, Gelber RD, Collins J, et al. (2000) Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer? Lancet 355: 1869–1874. doi: 10.1016/s0140-6736(00)02292-3
[21]
Anders CK, Hsu DS, Broadwater G, Acharya CR, Foekens JA, et al. (2008) Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression. J Clin Oncol 26: 3324–3330. doi: 10.1200/jco.2007.14.2471
[22]
Klein A, Olendrowitz C, Schmutzler R, Hampl J, Schlag PM, et al. (2009) Identification of brain- and bone-specific breast cancer metastasis genes. Cancer Lett 276: 212–220. doi: 10.1016/j.canlet.2008.11.017
[23]
Tham YL, Sexton K, Kramer R, Hilsenbeck S, Elledge R (2006) Primary breast cancer phenotypes associated with propensity for central nervous system metastases. Cancer 107: 696–704. doi: 10.1002/cncr.22041
[24]
Niwinska A, Pogoda K, Murawska M, Niwiński P (2011) Factors influencing survival in patients with breast cancer and single or solitary brain metastasis. Eur J Surg Oncol 37: 635–642. doi: 10.1016/j.ejso.2011.05.002
[25]
Nam BH, Kim SY, Han HS, Kwon Y, Lee KS, et al. (2008) Breast cancer subtypes and survival in patients with brain metastases. Breast Cancer Res 10: R20. doi: 10.1186/bcr1870
[26]
Altundag K, Bondy ML, Mirza NQ, Kau SW, Broglio K, et al. (2007) Clinicopathologic characteristics and prognostic factors in 420 metastatic breast cancer patients with central nervous system metastasis. Cancer 110: 2640–3647. doi: 10.1002/cncr.23088
[27]
Niwinska A, Murawska M (2012) New breast cancer recursive partitioning analysis prognostic index in patients with newly diagnosed brain metastases. Int J Radiat Oncol Biol Phys 82: 2065–2071. doi: 10.1016/j.ijrobp.2010.10.077
[28]
Marko NF, Xu Z, Gao T, Weil RJ (2012) Predicting survival in women with breast cancer and brain metastasis: A nomogram outperforms current survival prediction models. Cancer 118: 3749–3757. doi: 10.1002/cncr.26716
[29]
College of American Pathologists (2012). Protocal for the Examination of Specimens From Patients with Invasive Carcinoma of the Breast. Avalible: http://www.cap.org/apps/docs/committees/？cancer/cancer_protocols/2009/InvasiveBre？ast_09protocol.pdf Accessd Febuary 18, 2013.
[30]
Miller KD, Weathers T, Haney LG, Timmerman R, Dickler M, et al. (2003) Occult central nervous system involvement in patients with metastatic breast cancer: prevalence, predictive factors and impact on overall survival. Ann. Oncol 14: 1072–77. doi: 10.1093/annonc/mdg300
[31]
Kaplan MA, Inal A, Kucukoner M, Urakci Z, Ekici F, et al. (2013) Cranial magnetic resonance imaging in the staging of HER2-positive Breast Cancer Patients. Onkologie 36: 176–81. doi: 10.1159/000349950
